Clear Vision for Healthcare Investing
03.04.2014Oxford Immunotec Reports Fourth Quarter and Full Year 2013 Financial Results.
02.12.2014U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy.
More News >
Copyright © 2013 Clarus Ventures, LLC - All Rights Reserved